America's Last Mall King Is Still in Charge, Even After a Deadly Diagnosis
David Simon, the CEO of Simon Property Group, is battling cancer but has never been one to give up control.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Queen Camilla's ‘Health Issues' Revealed After King Charles' Cancer Found ‘Incurable'—She's on ‘Her Last Legs'
A lot of the conversation about the British Royal family in the last few years has been about the health of different members of the family. Sure, the feuds take a lot of the attention, but it's impossible to ignore that the health of various members of the royal family has been under scrutiny lately. This includes King Charles, who has cancer and is reportedly very sick, and Kate Middleton, who was diagnosed with cancer as well, and who is now cancer-free. Health speculation now includes Queen Camilla, too. The Queen is reportedly not doing very well, with a source telling RadarOnline, 'Camilla really is on her last legs – literally. Along with all her other health issues, she can now hardly walk.' More from StyleCaster Trump Accused of Stealing King Charles' Thunder After the Royal Made a Clear Stance Against the President Prince William Faces Devastating News After King Charles' Cancer Found 'Incurable' Related: See what Queen Camilla looked like throughout the years The source explained her issues in detail and what is being done to manage them. 'She gets these Sole Bliss shoes made by a company in London shipped into the palace by the truckload as she is trying to cover up her feet deformities on royal engagements. She has the shoes hand-tooled to cover up the bony looking growths on the sides of her feet and totters around in them trying to pretend like there's nothing wrong.' However, the source also added that 'sooner or later she could be headed for a wheelchair – if she lives much longer,' explaining that 'Her spending on medics and specialists is through the roof as she's too vain to admit she needs a wheelchair.' Reportedly, the Queen has been warned against painful surgery to remove bunions. The outlet also reports the Palace has hidden the Queen's ailments for a while, as she reportedly had to have surgery for a pickled liver due to her decades of drinking years ago. She also recently had pneumonia. However, it seems now the stress of her husband's illness and the desire not to appear crippled in public are putting great strain on her. All of this comes amid reports that King Charles' cancer is reportedly incurable, but manageable, according to royal writer and associate editor of the Daily Telegraph, Camilla Tominey. 'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' she wrote. Tominey also said that planning for Charles' 80th birthday in 2028, while 'very tentative,' is going ahead. Not just that, there are reportedly plans for King Charles and his son, Prince Harry, to reunite publicly at the Invictus Games in Birmingham in 2027. 'There is an awareness that the impasse cannot continue forever, not least if it starts to reflect badly on the king.' Prince Harry recently spoke of his desire to reconcile with his father, referencing his illness specifically, and indicating that he didn't know how long his father had left. The hope would be that the reunion would also include Prince Harry's kids. However, it looks like there are plenty of health concerns in the royal family, and right now, there's very little anyone can do but see how things develop. Best of StyleCaster The 26 Best Romantic Comedies to Watch if You Want to Know What Love Feels Like These 'Bachelor' Secrets & Rules Prove What Happens Behind the Scenes Is So Much Juicier BTS's 7 Members Were Discovered in the Most Unconventional Ways
Yahoo
16 minutes ago
- Yahoo
How Much the Average Middle-Class American Has Gained in the Stock Market Since Trump Announced His Tariffs
According to Gallup, 71% of middle-income Americans are invested in the stock market, and they've watched their fortunes rise and fall repeatedly during the volatile period since President Donald Trump announced his trade tariffs on April 2. But as the official start of summer approaches, those who resisted the urge to panic-sell during the frightening declines have largely seen their discipline pay off. Check Out: Read Next: It's impossible to gauge what the average middle-class investor might have gained or lost because the concept is a construct, regardless of the investor's socioeconomic class. Even if it were possible to put a dollar amount on the mean middle-class earner's stock investments, that would ignore critical variables like that investor's: Type, size and number of stock or fund holdings Portfolio makeup Portfolio diversity Degree of leverage from options trading or margin borrowing Trade frequency Fees and expenses Discover More: For context on just how differently two otherwise similar middle-class investors can perform, consider that Warner Bros Discovery Inc. (WBD) cratered on April 2 and retained a 24% overall loss through June 10. Conversely, Palantir Technologies Inc. (PLTR) has been one of the top performers in the post-tariff era, adding most of its 74% year-to-date gains since April 2. Two middle-class stock pickers with identical incomes and backgrounds who rolled the anti-diversification dice by purchasing identical amounts in either stock on April 1 would have had radically different outcomes between then and mid-June. A more reliable metric might be the major indices that so many middle-class households invest in through their 401(k)s, IRAs, index funds and ETFs. Between April 2 and June 10: The S&P 500, the benchmark index for the U.S. stock market, gained 6.16%. The Dow Jones Industrial Average, which tracks the blue chips, gained 1.31%. The tech-heavy and more volatile Nasdaq gained 11.57%. The FTSE All Cap Index, which includes much of the global stock market with 10,000 small-, mid- and large-cap companies in both developed and emerging markets, gained 7.22%. The average among all four is 6.57%, which is roughly what typical middle-class earners might have gained since April 2 if they followed the conventional advice of diversifying their portfolios with a blend of blue chips, growth stocks and foreign equities, and holding their positions regardless of market behavior. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Clever Ways To Save Money That Actually Work in 2025 7 Tax Loopholes the Rich Use To Pay Less and Build More Wealth This article originally appeared on How Much the Average Middle-Class American Has Gained in the Stock Market Since Trump Announced His Tariffs
Yahoo
29 minutes ago
- Yahoo
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
